Influence of DNA methyltransferase 3b on FHIT expression and DNA methylation of the FHIT promoter region in hepatoma SMMC-7721 cells

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 3, 2009, Pages 273-277

  Wang, Jia Xiang ^a   Zhang, Yong Gan ^a   Zhao, Long Shuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

DNA methyltransferase 3b; Fragile histidine trial; Gene expression; Liver neoplasms; Methylation

Indexed keywords

DNA METHYLTRANSFERASE 3B; FRAGILE HISTIDINE TRIAD PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ACID ANHYDRIDE HYDROLASES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; GENE SILENCING; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 67549106949     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Otto SP, Walbot V. DNA methylation in eukaryotes: kinetics of demethylation and de novo methylation during the life cycle. Genetics 1990;124:429-437. (Pubitemid 20066112)
2. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
3. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-859.
4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-174. (Pubitemid 30169152)
5. Razin A, Riggs AD. DNA methylation and gene function. Science 1980;210:604-610.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054. (Pubitemid 37448928)
7. Momparler RL. Cancer epigenetics. Oncogene 2003;22:6479-6483. (Pubitemid 37372327)
8. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002;3:748-754. (Pubitemid 35446744)
9. Toledo G, Sola JJ, Lozano MD, Soria E, Pardo J. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 2004;17:440-448. (Pubitemid 41646599)
10. Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Bader G, et al. Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 2004;40:1581-1588. (Pubitemid 38757747)
11. Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 2001;57:39-45. (Pubitemid 32532384)
12. Huber JC, Schneeberger C, Tempfer CB. Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 2002;42:1-12. (Pubitemid 34521716)
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428. (Pubitemid 34587077)
14. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193-198. (Pubitemid 36267086)
15. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
16. Weinstein IB. Addiction to oncogenes - the Achilles heal of cancer. Science 2002;297:63-64. (Pubitemid 34743088)
17. Nagai M, Nakamura A, Makino R, Mitamura K. Expression of DNA (5-cytosin)-methyltransferases (DNMTs) in hepatocellular carcinomas. Hepatol Res 2003;26:186-191.
18. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003;105:527-532. (Pubitemid 36578558)
19. Majumder S, Ghoshal K, Datta J, Bai S, Dong X, Quan N, et al. Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma. J Biol Chem 2002;277:16048-16058. (Pubitemid 34967889)
20. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001;61:4238-4243. (Pubitemid 32720994)
21. Park HJ, Yu E, Shim YH. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett 2006;233:271-278. (Pubitemid 43327383)
22. Vallböhmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 2006;8:39-44. (Pubitemid 44336242)
23. Soejima K, Fang W, Rollins BJ. DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 2003;22:4723-4733. (Pubitemid 36976447)
24. Chen T, Tsujimoto N, Li E. The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol Cell Biol 2004;24:9048-9058. (Pubitemid 39313909)